Literature DB >> 33876375

Comparative genomics of invasive Streptococcus pneumoniae CC320/271 serotype 19F/19A before the introduction of pneumococcal vaccine in India.

Rosemol Varghese1, Ayyanraj Neeravi1, Jobin John Jacob1, Karthick Vasudevan1, Jones Lionel Kumar1, Nithya Subramanian2, Balaji Veeraraghavan3.   

Abstract

The emergence of multi drug resistant clone CC320 serotype19F/19A and their capsular (cps) antigenic variants due to selective pressures such as vaccine had been reported worldwide. Hence, it is important to identify the prevalent clones, sequence types and cps variants of serotype 19F/19A in India, where PCV13 has been recently introduced. Multi-locus sequence typing (MLST) was performed for all (n = 21) invasive S. pneumoniae isolates of serotype 19A (n = 5) and 19F (n = 16) collected between the years 2012 and 2018 from children less than 5 years. The genome characterization by whole genome sequencing for the Sequence types (STs) 320 and 271(n = 7) were performed and compared with another six Indian WGSs of similar STs available from the GPS platform. The predominant STs in the serotype 19F/19A study isolates were of CC320: ST 320, 236 and 271, associated with PMEN clone Taiwan19F-14. The WGSs of CC320 study isolates showed high genomic similarity to the Taiwan19F-14 clone, and the penicillin binding protein (PBP) amino acid sequence similarity was 100% for PBP1A, 93% for PBP 2B and 2X. Whilst PBP comparison with other global MDR ST320 strains revealed that the ST320 clones in India are of low-level penicillin resistance. The presence of a few ST320/19A/19F invasive isolates with high similarity to the Taiwan clone suggests slow and gradual expansion of Taiwan19F-14 associated CC320 clones in India. Since serotype 19F/19A is covered by PCV13 vaccine, the expansion of 19F/19A cones with non-PCV13 vaccine serotype in India should be monitored.

Entities:  

Keywords:  CC320; India; Penicillin binding proteins; Penicillin resistance; S. pneumoniae; Serotype 19

Year:  2021        PMID: 33876375     DOI: 10.1007/s11033-021-06353-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  44 in total

1.  Clonal replacement among 19A Streptococcus pneumoniae in Massachusetts, prior to 13 valent conjugate vaccination.

Authors:  W P Hanage; C J Bishop; G M Lee; M Lipsitch; A Stevenson; S L Rifas-Shiman; S I Pelton; S S Huang; J A Finkelstein
Journal:  Vaccine       Date:  2011-09-29       Impact factor: 3.641

2.  Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study.

Authors:  So Hyun Kim; Jae-Hoon Song; Doo Ryeon Chung; Visanu Thamlikitkul; Yonghong Yang; Hui Wang; Min Lu; Thomas Man-Kit So; Po-Ren Hsueh; Rohani M Yasin; Celia C Carlos; Hung Van Pham; M K Lalitha; Nobuyuki Shimono; Jennifer Perera; Atef M Shibl; Jin Yang Baek; Cheol-In Kang; Kwan Soo Ko; Kyong Ran Peck
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

3.  Mutations in pneumococcal cpsE generated via in vitro serial passaging reveal a potential mechanism of reduced encapsulation utilized by a conjunctival isolate.

Authors:  Mara G Shainheit; Michael D Valentino; Michael S Gilmore; Andrew Camilli
Journal:  J Bacteriol       Date:  2015-03-16       Impact factor: 3.490

4.  Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain.

Authors:  Carmen Ardanuy; Dora Rolo; Asunción Fenoll; David Tarrago; Laura Calatayud; Josefina Liñares
Journal:  J Antimicrob Chemother       Date:  2009-06-17       Impact factor: 5.790

5.  Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005.

Authors:  Matthew R Moore; Robert E Gertz; Robyn L Woodbury; Genevieve A Barkocy-Gallagher; William Schaffner; Catherine Lexau; Kenneth Gershman; Arthur Reingold; Monica Farley; Lee H Harrison; James L Hadler; Nancy M Bennett; Ann R Thomas; Lesley McGee; Tamara Pilishvili; Angela B Brueggemann; Cynthia G Whitney; James H Jorgensen; Bernard Beall
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

6.  Single-step capsular transformation and acquisition of penicillin resistance in Streptococcus pneumoniae.

Authors:  Krzysztof Trzciński; Claudette M Thompson; Marc Lipsitch
Journal:  J Bacteriol       Date:  2004-06       Impact factor: 3.490

7.  Pneumococcal Capsule Synthesis Locus cps as Evolutionary Hotspot with Potential to Generate Novel Serotypes by Recombination.

Authors:  Rafal J Mostowy; Nicholas J Croucher; Nicola De Maio; Claire Chewapreecha; Susannah J Salter; Paul Turner; David M Aanensen; Stephen D Bentley; Xavier Didelot; Christophe Fraser
Journal:  Mol Biol Evol       Date:  2017-10-01       Impact factor: 16.240

8.  Streptococcus pneumoniae serotype 19A in children, South Korea.

Authors:  Eun Hwa Choi; So Hee Kim; Byung Wook Eun; Sun Jung Kim; Nam Hee Kim; Jina Lee; Hoan Jong Lee
Journal:  Emerg Infect Dis       Date:  2008-02       Impact factor: 6.883

9.  Vaccine escape recombinants emerge after pneumococcal vaccination in the United States.

Authors:  Angela B Brueggemann; Rekha Pai; Derrick W Crook; Bernard Beall
Journal:  PLoS Pathog       Date:  2007-11       Impact factor: 6.823

10.  Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations.

Authors:  Pontus Naucler; Ilias Galanis; Eva Morfeldt; Jessica Darenberg; Åke Örtqvist; Birgitta Henriques-Normark
Journal:  Clin Infect Dis       Date:  2017-11-13       Impact factor: 9.079

View more
  1 in total

1.  Emergence of Meropenem Resistance Among Cefotaxime Non-susceptible Streptococcus pneumoniae: Evidence and Challenges.

Authors:  Rosemol Varghese; Soumya Basu; Ayyanraj Neeravi; Agilakumari Pragasam; V Aravind; Richa Gupta; Angel Miraclin; Sudha Ramaiah; Anand Anbarasu; Balaji Veeraraghavan
Journal:  Front Microbiol       Date:  2022-02-03       Impact factor: 5.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.